de Gramont schedule is a very low toxic and effective regimen in low performance status patients affected by metastatic gastric cancer: preliminary report

Treatment of patients affected by metastatic gastric cancer with low performance status (PS) is a very hard choice. It is mandatory to define a very well-tolerated schedule to be employed in these subgroup of patients. From June 1999 to December 2001, 21 patients (pts) affected by metastatic gastric...

Full description

Saved in:
Bibliographic Details
Published in:Tumori 2002-07, Vol.88 (4), p.A21-A24
Main Authors: Rea, Antonio, Caldarola, Gennaro Gadaleta, Sandomenico, Claudia, Colangelo, Mauro, Filice, Aldo, Mastroianni, Candida Maria, Biamonte, Rosalbino, Palazzo, Salvatore
Format: Article
Language:English
Subjects:
Adult
Aged
Antimetabolites, Antineoplastic - administration & dosage
Drug Administration Schedule
Female
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Humans
Male
Middle Aged
Neoplasm Metastasis
Stomach Neoplasms - drug therapy
Stomach Neoplasms - mortality
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of patients affected by metastatic gastric cancer with low performance status (PS) is a very hard choice. It is mandatory to define a very well-tolerated schedule to be employed in these subgroup of patients. From June 1999 to December 2001, 21 patients (pts) affected by metastatic gastric cancer with low performance status (> or = 2 ECOG) were treated with bimonthly "de Gramont" schedule. Treatment was planned to perform 6 courses of chemotherapy for each patient plus other 2-4 if a response had been documented. A total of 161 courses of de Gramont schedule was administered to the 21 pts enrolled. We observed 8 PD (38%), 8 SD (38%), 5 objective responses (24%--2 MR, 3 PR). Duration of objective responses (OR) was 5 months, 3 months for 3 PRs and 2 and 1 months for two MRs respectively. At time of observation (June 2002) median overall survival (OS) was 14 months, median survival from the starting de Gramont schedule was 8 months. Toxicity was very mild: grade 3 leukopenia in 1 pt, grade 1-2 anemia and piastrinopenia in 3 pts, grade 1-2 nausea vomiting in 5 pts, grade 1 diarrhea in 4 pts, grade 3 mucositis in 2 pts. No other side effect was renowned. PS ameliorated in 12 (57%) pts, even if a major response was not noted. de Gramont schedule can be safely and effectively employed in metastatic gastric cancer pts with very low performance status.
ISSN:0300-8916
2038-2529
DOI:10.1177/030089160208800473